When: Tuesday, May 6, 2014, 6:00 – 9:00 pm
Where: Lowenstein Sandler LLP, 390 Lytton Ave., Palo Alto, CA 94301
Sarvajna Dwivedi, Ph.D., co-founder and Chief Scientific Officer of Pearl Therapeutics, Inc., will describe the scientific, clinical and organizational excellence required to take Pearl from a start-up to a $1.15 B acquisition by AstraZeneca. Listen to the scientific story of inventing a formulation platform, generating a vast amount of clinical evidence in the challenging arena of chronic obstructive pulmonary disease and assembling an organization that prepared three products for Phase III studies within 5 years. Dr. Dwivedi will also describe how Pearl raised its initial capital, recruited top management, implemented a multi-state, multi-site operational model and overcame technical challenges to rapidly progress its products through development. Pearl is now a thriving entity under the AstraZeneca umbrella, with an expanding pipeline and a strong potential to impact indications related to breathing impairment.
EPPIC Members / Charter Members / Sponsors: Complimentary
EPPIC Non-members: $15
Please visit eppicglobal.org to learn more about the event and EPPIC.
Sarvajna Dwivedi, Ph.D.
Co-Founder and Chief Scientific Officer, Pearl Therapeutics, Inc.
Dr. Dwivedi, co-founder of Pearl Therapeutics and now CSO of the division at AstraZeneca, has extensive prior experience in drug development at Glaxo, Dura, Alkermes and Nektar. He was involved in the development of over 40 molecules in various therapeutic classes and dosage forms from discovery to commercialization. At Nektar, he served as the Director of Product Development, responsible for new product identification, design, planning and development efforts. At Alkermes, he served as the Director of Delivery Systems, responsible for the engineering and development of inhalers for multiple products. At Dura, Dr. Dwivedi led and managed formulation design and development efforts for various Spiros programs. Earlier, at Glaxo, Dr. Dwivedi was involved in the development, manufacturing and approval of Flovent® Diskhaler, Serevent® Diskus, Advair® Diskus, Relenza® Diskhaler and Ventolin® Evohaler. In addition to his product development experience, Dr. Dwivedi has led and conducted technical due diligence efforts for in-licensing, out-licensing and acquisition opportunities. Dr. Dwivedi holds M.Sc. and Ph.D. degrees in Pharmaceutical Sciences from the University of British Columbia and M.Pharm. and B.Pharm.(Hons) from Banaras Hindu University in India.